Rain Therapeutics Announces Presentations on Tarloxotinib at the 30th EORTC-NCI-AACR Symposium

 
 

FREMONT, Calif., November 6, 2018 -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data from ongoing studies of Rain’s lead candidate, tarloxotinib, at the 30th annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held November 13-16, 2018 in Dublin, Ireland. Rain collaborators at the University of Auckland and the University of Colorado, Denver will present three posters detailing the efficacy of tarloxotinib in preclinical models. 

Details on the presentations are as follows:  

Presentation Title: Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
Presenter: Adriana Estrada-Bernal, Ph.D., University of Colorado, Denver
Date: November 13, 2018 
Poster Viewing Time: 12:00 p.m. – 6:30 p.m. GMT

Presentation Title: The hypoxia-activated EGFR/HER2 inhibitor Tarloxotinib is activated by the plasma membrane reductase STEAP4
Presenter: Shevan Silva, Ph.D., University of Auckland 
Date: November 16, 2018 
Poster Viewing Time: 10:00 a.m. – 2:00 p.m. GMT

Presentation Title: Targeting tumour hypoxia with tarloxotinib improves the therapeutic efficacy of checkpoint blockade
Presenter: Regan Zhe Fu, MSc, University of Auckland 
Date: November 16, 2018 
Poster Viewing Time: 10:00 a.m. – 2:00 p.m. GMT

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain Therapeutics website after the presentations conclude.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.
The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

About the Doebele Laboratory, University of Colorado, Denver
The Doebele laboratory at the University of Colorado Anschutz Medical Campus focuses on  generating unique patient-derived cancer models, including human cancer cell lines, to study specific oncogene-driven cancers. The lab has successfully defined intrinsic and acquired resistance mechanisms for ALK and ROS1-driven cancers and was the first to identify NTRK1 gene fusions in lung cancer, generating the pre-clinical data that led to the development of TRK inhibitors for lung and other cancers harboring NTRK gene fusions. More recently, the lab has turned to tackling the clinical problem of treating EGFR exon 20 and HER2 exon 20 mutations as well as other HER-family receptor tyrosine kinase-driven cancers. Ultimately, the lab’s goal is to advance personalized medicine through the identification, analysis, and rational targeting of driver oncogenes in cancer in order to improve the clinical outcomes of patients.

Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com